Syncona Ltd on Friday said that its portfolio company, Beacon Therapeutics Holdings Ltd, has presented data at a conference in Barcelona.
Syncona is a London-based life science investor that owns a diversified portfolio of companies spanning across clinical stages. Beacon Therapeutics is an investee of Syncona, and an ophthalmic gene therapy company.
The data comprises 36-month interim safety and efficacy results from Beacon’s Phase I/II Horizon trial of its lead asset, AGTC-501, in patients with X-linked retinitis pigmentosa.
With safety the primary endpoint of the trial, the results showed that AGTC-501 continues to be well-tolerated with no clinically significant safety events related to the therapy.
‘This data presented by Beacon highlights the strong safety profile of this therapy, as well as promising efficacy signals and a continued durability profile out to 36 months post-dosing, which is particularly pleasing for an exploratory Phase I/II trial,’ said Chief Executive Officer Chris Hollowood.
‘We now look forward to the upcoming 24-month data read-out from the Phase II SKYLINE trial which has the benefit of an optimised dose and greater surgical repeatability. The Beacon team continue to execute well, with both the Phase II DAWN and Phase II/III registrational VISTA trials currently recruiting patients following the introduction of an improved manufacturing process.’
Shares in Syncona were trading 0.9% lower at 111.00 pence each in London on Friday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
